Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well trametinib works in treating patients with
hormone-resistant prostate cancer that is growing or getting worse and has spread to other
parts of the body. Trametinib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborators:
National Cancer Institute (NCI) Novartis Prostate Cancer Foundation Stand Up To Cancer